CMV intraocular implant effective. CMV retinitis and potent antiviral therapy. Hopeful CMV drug stalled. CMV retinitis may develop following antiretroviral therapy. Update on cidofovir for CMV retinitis.
Systemic therapy lowers risk of bilateral CMV retinitis.
Roche puts ganciclovir prodrug program on hold. Oral manifestations of HIV infection. See p. 31. See p. 45-46. Cidofovir effectively delays CMV retinitis.